Sobha Sivaprasad

2 months ago | nature.com | Sobha Sivaprasad

We are grateful to Chen et al. for their commendations and suggestions for progressing this field. Competing risks (events that preclude primary event occurrence) feature in almost all Kaplan–Meier analyses and hazard estimates can be susceptible to competing risk bias; but only if featured frequently and treated as censored events [1]. We can fortunately offer reassurance that the risks nominated by Chen et al. have minimal if any, impact on our results presented.

2 months ago | nature.com | Sobha Sivaprasad

In the phase 2/3 PHOTON trial, patients with diabetic macular oedema who received aflibercept 8 mg every 12 or 16 weeks achieved similar visual and anatomic improvements to those treated with aflibercept 2 mg every 8 weeks at Week 48. AcknowledgementsThe authors thank Yazmin Madrigal for visual graphics and layout support. The authors also acknowledge Disha Patel, PhD, for medical writing assistance. FundingThe PHOTON trial (NCT04429503) was co-funded by Regeneron Pharmaceuticals, Inc.

Jan 13, 2025 | thelancet.com | Sobha Sivaprasad

References1. Scanlon, PHThe English national screening programme for sight-threatening diabetic retinopathyJ Med Screen. 2008; 15:1-42. Liew, G ∙ Michaelides, M ∙ Bunce, CA comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010BMJ Open. 2014; 4, e0040153. Leal, J ∙ Luengo-Fernandez, R ∙ Stratton, IM ∙ et al.

Aug 30, 2024 | nature.com | Sobha Sivaprasad |Clare Bailey |Giuliana Silvestri

AbstractSome eyes with neovascular age-related macular degeneration (nAMD) and centre-involving diabetic macular oedema (DMO) fail to respond sufficiently or lose response over time to standard of care intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. This paper explores clinical scenarios for switching to dual action angiopoietin-2 (Ang-2)/VEGF-A inhibitor faricimab (Vabysmo, Roche Products Limited) in previously anti-VEGF-treated patients.

Aug 26, 2024 | nature.com | Ashish Sharma |Peter Kaiser |Frank G. Holz |Sobha Sivaprasad |Taku Wakabayashi |Nilesh Kumar | +3 more

The majority (95.2%) of the ophthalmologists were aware of all the ranibizumab biosimilars available in India. Biosimilar ranibizumab was the most common ranibizumab administered with 50–100% usage in 51% respondents whereas the proportion of originator usage was below 25% in the majority of practices (62.8%) (Fig. 1B).